Hundreds of stem students explore Owensboro Air Show roles at mid-america jet
OWENSBORO, Ky. (WEHT) — In Owensboro, students interested in aviation got a behind the scenes look today at the Owensboro Air Show. A stem event was hosted at Mid-America Jet for 3 local schools looking to help the next generation take flight.
Tim Ross, the director of public events in Owensboro, says hosting events like these in the Spring versus during airshow weekend allows students the chance for more of a hands-on experience with the machinery. They get to ask questions and learn about the numerous other positions that make everything possible.
On Thursday, hundreds of students got a chance to take a step beyond the aircrafts' performances. Stem students at Owensboro Innovation Academy, Apollo High School and Daviess County High School all made their rounds at Mid-America Jet.
'[It gives] them a time to talk to these pilots and his crew…whether or not it's the maintainers or the medics or the pilots. 'How do they get started in their field? What they enjoy doing? What their day to day looks like in their field?',' says Ross.
Some students even got to switch seats with the pilot and take a look at flight simulations. Captain Sam Williams piloted the C-130 Hercules,a four engine transport aircraft.
'Total fuel is about 42,000 pounds. Which is relatively small in [comparison to] the other Air Force mobility aircraft.'
Preson Estes says it was actually his love of Lego's that allowed him to discover his dream of one day constructing aircrafts.
'I've seen how much wiring, and how much that stuff requires. It's very complex. It's going to take a lot. I'm ready to take that challenge,' says Estes.
Isabel Pierrard likes aerospace but says, at the moment, her fear of heights has her aiming for a job that keeps her on the ground.
'I have more of an incline for creativity rather than mathematical and strategical. I felt really welcomed as a female. It's pretty male dominated from what I can see today, but it also feels good that we, as girls in this century, had this chance to see all these aircrafts and learn,' says Pierrard.
Owensboro officials say after the event, they speak with teachers and students to explore unique ways they can continue to explore roles.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 days ago
- Yahoo
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
5 days ago
- Yahoo
Physicists use AI to hunt for UAPs and UFOs
An international team of physicists has developed a new methodology to aid NASA and other government agencies in their ongoing investigations into unidentified aerial phenomena (UAPs). The result is a novel strategy integrating a specially designed artificial intelligence program that was partially inspired by the physicists' own hunt for elusive dark matter. More popularly known as unidentified flying objects or UFOs, UAPs aren't necessarily considered as outlandish as they were decades ago. Setting aside the various theories that point to mysterious visitors from another planet, analysis increasingly centers on determining more worldly explanations. UAPs are often explained by classified experimental aircraft, astronomical events, or simply a case of mistaken drone identity. Meanwhile, a small percentage of sightings continue to baffle experts. Over the last few years, the US government has attempted to present a more transparent approach to its UAP research, while the military continues a campaign to destigmatize reporting sightings among its ranks. In November 2024, Congress held a publicly televised joint subcommittee hearing about UAPs featuring a former US Navy rear admiral and NASA administrator. While not without its fair share of criticism, these and similar events are shifting the overarching narrative around unidentified aerial phenomenon. Researchers like Matthew Syzdagis at the University of Albany have followed this evolving discourse for years. An associate professor of physics focused on dark matter, Syzdagis recently began collaborating with over 30 colleagues around the world to determine if this approach to hunting dark matter could be adapted to the search for UAPs. Their results, published this month in the journal Progress in Aerospace Studies, offer a new interdisciplinary methodology to review the past and future UAP sightings. 'As this process moves forward, it's critical that future study of UAPs follows a rigorous, repeatable method that can be tested and confirmed by other researchers,' Syzdagis said in a statement. 'We aim to establish a roadmap for these efforts with this paper.' The team relied on an array of datasets and tools to build their framework, including publicly available Doppler weather information from the National Weather Service (NWS). The NWS data was used to corroborate observations from additional equipment and determine if any of them simultaneously recorded a given anomaly. They then utilized Cosmic Watch, a radiation-detection system, to assess if a target UAP observed by infrared cameras was accompanied by ionizing radiation. To help analyze the infrared data, Szydagis created a new software program called Custom Target Analysis Protocol (C-TAP) that utilizes machine learning alongside human verification to review individual camera frames on a pixel-by-pixel basis. Inspired by similar strategies used to scan for direct evidence of dark matter, C-TAP then flags and separates actual UAP observations from any digital noise. Finally, these results were overlaid with trigonometric calculations to exclude any known objects in the sky like satellites or the International Space Station. To test it all out, Szydagis and colleagues used their new methodology to review observable light and infrared images collected on a 2021 field expedition around Laguna Beach, California, amid a period of heightened UAP reports. In total, the team reviewed about one hour of triggered visible and night-vision video footage along with over 600 hours of infrared data and 55 hours of background radiation measurements. Of the multiple anomalies initially flagged, researchers were able to offer plausible and likely explanations for all sightings except for one—a collection of bright white dots inside a dark spot recorded across multiple videos. And even then, it seems unlikely that the UAP event was unique. 'At this point, none can be classified as true anomalies, although further study of remaining ambiguities may alter this conclusion,' the study's authors wrote in their conclusion. Moving forward, the team hopes their methodology will help more researchers around the world continue to vet UAP sightings on a scientific, unbiased basis. 'Given the longstanding, global nature of the UAP/UFO question, [and] the air safety and security implications of their presence… studying and understanding these phenomena is of great and urgent importance,' added University of Albany physics professor and study lead author Kevin Knuth.
